Bay State Biotech Report: Sage Receives Takeover Interest
Bay State Biotech Report
Sage Receives Takeover Interest
Sage Therapeutics' CEO Jeff Jonas told Bloomberg's Doni Bloomfield that the drugmaker is "on top of everyone's M&A list,'' and has been "hearing a great deal from a lot of companies.'' Shares surged on the news. Jonas also discusses the company's experimental therapy for major depression disorder. That's on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host Anne Mostue discuss the latest in biotech news from the Boston area and across the nation.
Feb 16, 2017